The acquisition of Mission Cancer + Blood by UI Health has sparked controversy, with patients facing significantly higher costs for routine care. The author, Lee Rood, delves into the issue, highlighting the unexpected surge in charges post-acquisition. Rood argues that the hospital-based billing approach, while common, often leads to increased costs for patients, especially those with limited financial resources. The situation is further exacerbated by the fact that UI Health, being a tax-exempt state institution, should prioritize affordability and accessibility. Rood's personal experience with a sudden $1,991 bill for a routine visit underscores the impact of these changes on patients. The article also mentions the broader trend of hospital systems acquiring independent clinics, leading to higher costs and potential barriers to care for many Americans. Rood calls for legislative action to address the affordability of cancer care and limit hospital rates for outpatient services, emphasizing the need for a more patient-centric approach in healthcare.
